PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629296
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629296
Targeted Sequencing and Resequencing Market size was valued at US$ 6,124.67 Million in 2024, expanding at a CAGR of 22.6% from 2025 to 2032.
The targeted sequencing and resequencing market focuses on high-throughput sequencing technologies that enable the precise analysis of specific genes or regions of the genome, offering improved resolution compared to whole-genome sequencing. Increased adoption of next-generation sequencing (NGS) techniques in oncology, precision medicine, and genetic research has contributed to market growth. For instance, nearly 40% of researchers in the genomics field reported using targeted sequencing methods for genetic studies in 2023. Factors such as growing demand for personalized medicine, technological advancements in sequencing tools, and increased healthcare investments further propel market growth. However, high costs associated with sequencing equipment and data storage, along with a lack of skilled professionals, may hinder broader adoption. On the other hand, market opportunities exist in developing regions where genetic testing demand is rapidly increasing, along with advancements in cloud-based platforms for better data storage and management. Partnerships between academic institutions and biotech companies are also fostering innovation in targeted sequencing technology.
Targeted Sequencing and Resequencing Market- Market Dynamics
Rising Demand for Personalized Medicine Drives Growth in the Targeted Sequencing and Resequencing Market
The growing demand for personalized medicine is fueling the expansion of the targeted sequencing and resequencing market. Advancements in genomic technologies have enabled precise patient stratification and drug development. The U.S. National Institutes of Health (NIH) has invested significantly in genomics to support personalized therapies, with over $200 million allocated to research in 2020 alone. This surge in research is helping in the development of more accurate diagnostic and therapeutic tools. Additionally, targeted sequencing plays a pivotal role in oncology, with clinical trials showcasing that targeted therapies can enhance survival rates. Moreover, the ongoing initiatives by healthcare institutions to tailor treatments based on individual genetic profiles are driving the adoption of targeted sequencing, helping to achieve better outcomes in cancer and rare genetic disorders.
Targeted Sequencing and Resequencing Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 22.6% over the forecast period (2025-2032)
Based on Technology segmentation, Sequencing Technology was predicted to show maximum market share in the year 2024
Based on Type segmentation, DNA-based Targeted Sequencing was the leading Type in 2024
Based on Application segmentation, Clinical Applications was the leading Application in 2024
On the basis of region, North America was the leading revenue generator in 2024
The Global Targeted Sequencing and Resequencing Market is segmented on the basis of Technology, Type, Application, End-User, and Region.
The market is divided into two categories based on Technology: Sequencing and Re-sequencing. Sequencing holds the highest market share due to its broad application in clinical diagnostics and research. Re-sequencing follows closely, offering crucial insights into genetic variations and aiding in personalized medicine and disease management.
The market is divided into two categories based on Type: DNA-based Targeted Sequencing and RNA-based Targeted Sequencing. DNA-based targeted sequencing leads due to its widespread use in genetic analysis and disease detection. RNA-based targeted sequencing follows, offering critical insights into gene expression and regulation, particularly in cancer research and drug development.
Targeted Sequencing and Resequencing Market- Geographical Insights
The targeted sequencing and resequencing market is witnessing strong growth across various regions, driven by advancements in genomics and personalized medicine. North America holds the largest market share, primarily due to the presence of major biotech firms, strong research funding from institutions like the National Institutes of Health (NIH), and the growing adoption of targeted therapies in cancer treatment. The U.S. is a key player, with significant investments in precision medicine, contributing to the region's dominance. Europe also plays a crucial role, with countries like Germany, the UK, and France increasing their focus on genomic research and precision healthcare. The Asia-Pacific region is emerging as a high-growth area, driven by rising healthcare expenditure, government initiatives, and the growing demand for advanced diagnostic tools. China and India are particularly expanding their genetic research capabilities, fostering an environment conducive to market growth. The Latin American and Middle Eastern markets are expected to show significant potential due to increasing awareness and rising healthcare investments.
The targeted sequencing and resequencing market is highly competitive, with several key players leading the charge in technological advancements and product offerings. Companies like Illumina, Thermo Fisher Scientific, and Roche are at the forefront, offering cutting-edge sequencing platforms, reagents, and services. Illumina dominates the market with its next-generation sequencing (NGS) technology, which is widely used in clinical diagnostics, research, and drug development. Thermo Fisher Scientific also plays a significant role, providing sequencing solutions and bioinformatics tools that are crucial for targeted sequencing. Roche offers comprehensive genomic solutions through its acquisition of companies like Foundation Medicine, focusing on precision oncology. Emerging players such as Pacific Biosciences and Qiagen are enhancing their offerings with long-read sequencing technologies and new kits. In addition to these, several biotechnology firms and academic institutions are focusing on niche applications like rare genetic disorders, personalized medicine, and targeted drug discovery, intensifying market competition. Strategic collaborations, mergers, and acquisitions are common strategies to strengthen market positions and expand product portfolios in this rapidly evolving space.
In March 2024, The WHO launched new guidance on targeted next-generation sequencing (NGS) tests for diagnosing drug-resistant tuberculosis, enhancing rapid detection of drug resistance. Additionally, a TB sequencing portal was introduced, featuring over 56,000 sequences to support research and diagnostics.
In May 2024, Baylor Genetics introduced its RNA sequencing test, RNAseq, for Whole Exome and Whole Genome Sequencing (WES/WGS). Additionally, the company reduced the turnaround time for WES and WGS to three weeks, offering reports within five days.